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ABSTRACT
Although probability of event-free survival in pediatric lymphoblastic T-cell 
lymphoma (T-LBL) is about 75%, survival in relapsed patients is very poor, so the 
identification of new molecular markers is crucial for treatment optimization. Here, we 
demonstrated that the over-expression of miR-223 promotes tumor T-LBL cell growth, 
migration and invasion in vitro. We found out that SIK1, an anti-metastatic protein, 
is a direct target of miR-223 and consequently is significantly reduced in miR-223-
overexpressing tumor cells. We measured miR-223 expression levels at diagnosis in 
tumor biopsies from 67 T-LBL pediatric patients for whom complete clinical and follow 
up data were available, and we found that high miR-223 expression (above the median 
value) is associated with worse prognosis (PFS 66% vs 94%, P=0.0036). In addition, 
the multivariate analysis, conducted taking into account miR-223 expression level and 
other molecular and clinical characteristics, showed that only high level of miR-223 is 
an independent factor for worse prognosis. MiR-223 represents a promising marker 
for treatment stratification in pediatric patients with T-LBL and we provide the first 
evidence of miR-223 potential role as oncomir by SIK1 repression.
INTRODUCTION
Childhood Lymphoblastic T-cell Lymphoma 
(T-LBL) represents about one-third of pediatric non-
Hodgkin lymphomas (NHLs), and it originates from 
lymphoid progenitor cells arrested at early stages of T-cell 
maturation [1]. Patients with T-LBL often present with 
large mediastinal masses and generally no morphological 
bone marrow involvement. Indeed, since cell marker 
expression overlaps with that of T-lineage acute 
lymphoblastic leukemia (T-ALL), the clinical distinction 
between the two entities is arbitrarily determined by 
the degree of bone marrow involvement: patients with 
more than 25% of lymphoblasts in the bone marrow are 
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classified as affected by T-ALL, whereas those with a 
lower degree of marrow replacement or no detectable 
lymphoblasts are classified as T-LBL patients [1]. 
Although the 5-year event-free survival (EFS) and overall 
(OS) survival for pediatric T-LBL patients substantially 
improved during the last decades, the prognosis of 
patients who suffered from a relapse remains poor [2, 
3]. Furthermore, the intensive treatment regimens are 
accompanied by high toxicity with considerable mortality 
and morbidity, indicating a need for the identification of 
prognostic markers to allow early group stratification and 
design of risk-adjusted treatment protocols. Until now, 3 
molecular markers have been reported in literature, which 
might be of prognostic relevance for pediatric T-LBL 
patients treated on BFM (Berlin-Munster-Frankfurt) 
based regimens: aberrations in chromosome 6q14-24, 
mutations of NOTCH1 and/or FBXW7 and mutations 
of PTEN [4]. In descriptive retrospective analyses of 
pediatric T-LBL patients, loss of heterozygosity (LOH) at 
chromosomal region 6q14-24 (LOH6q) has been shown 
to be significantly associated with adverse outcome and 
increased risk of relapse [2, 4]. In the largest study by 
Bonn et al., LOH6q was observed in 12% of patients 
and the common deleted region and thus the region 
of main interest for the unfavorable prognosis was 
located at chromosome 6q16 [4]. Hotspot mutations in 
NOTCH1 and/or FBXW7 are observed in about 50% of 
pediatric T-ALL patients and reported to be associated 
with an improved treatment response or outcome [5, 6]. 
Concerning pediatric T-LBL patients, five studies were 
published dealing with NOTCH1 and/or FBXW7 mutations 
[4, 7, 8]. Bonn et al. observed NOTCH1 mutations in 60% 
of patients and associated with a favorable prognosis [4]. 
Similar data were reported for pediatric patients with 
T-ALL treated according to the ALL-BFM protocol [9, 
10], a comparable regimen to that of NHL-BFM group 
administered to T-LBL patients, suggesting that NOTCH1 
mutations might serve as a positive prognostic marker in 
the context of BFM-type treatment.
Comprehensive data about non-coding transcripts, 
such as microRNAs (miRNAs), are available for many 
hematological malignancies. We recently identified a 
miRNA expression profile specific for pediatric T-LBL 
[11], suggesting that few miRNAs, including miR-223, 
may play a major role in T-LBL pathogenesis. Over-
expression of miR-223 has been previously reported 
in T-ALL, where miR-223 has been shown to promote 
the development of leukemia in a mouse model [12]. 
Moreover, FBXW7 has been identified as a main mediator 
of miR-223 pro-oncogenic activity in T cells [13, 14]. 
These observations suggest that miR-223 overexpression 
may provide an additional level of regulation to promote 
NOTCH1 signaling by repressing its negative modulator 
FBXW7. In the present study, we assessed for the first 
time the clinical and prognostic significance of miR-223 in 
a large series of pediatric T-LBL cases and its correlation 
with NOTCH1/FBXW7 mutational status and protein 
expression. Our data show that in patients with T-LBL 
miR-223 has a prognostic value that appears to outweigh 
the prognostic value of NOTCH1 mutations. In addition, 
our data suggest that the anti-metastatic SIK1 is a target of 
miR-223 and over-expression of miR-223 contributes to a 
more aggressive tumor phenotype.
RESULTS
Clinical features
To ensure that the study population with appropriate 
bioptic material was representative of the entire clinical 
cohort, we compared the EFS of the 67 analyzed patients 
with that of all the 114 patients enrolled in treatment 
protocols and no statistically significant differences 
were found (EFS= 78%, SE=5%, vs EFS=77%, SE= 
4%, respectively, p=0.93) (Supplementary Table 1). The 
67 patients with T-LBL evaluated for molecular markers 
had a median age of 9.3 years (range 1.1-16.6); most of 
them (89%) were diagnosed with disease at stage III-
IV according to the St Jude’s classification [15]; three 
of 67 had Central Nervous System (CNS) involvement. 
The main clinical characteristics of the 67 patients with 
T-LBL are listed in Table 1, along with the univariate 
and multivariate analyses to account for the variables 
of gender, stage of disease, age at diagnosis, CNS 
involvement, bone marrow involvement, mediastinal 
involvement, in addition to NOTCH1 mutational status 
and miR-223 expression level. The median follow-up 
of patients was 6.3 years (range: 0.7-14.5). Sixty-six 
(98.5%) of 67 patients reached complete remission 
during induction treatment. A total of 14 patients had a 
treatment failure due to: induction failure (n=1); death 
in first remission (n=1 as a result of septicemia); disease 
relapse (n=13; n=6 local, and n=7 local and new site), after 
a median time of 1.4 years from diagnosis (range 0.5-7.1 
years). Of the 13 relapsed patients, only 3 are alive after 
autologous (n=1) or allogenic (n=2) hematopoietic stem-
cell transplantation (HSCT), whereas 10 died as a result of 
disease progression despite second-line treatments.
miR-223 is over-expressed in T-LBL cases
We previously defined a T-LBL specific miRNA 
signature that includes miR-223 as specifically over-
expressed in T-LBLs compared to their normal counterpart 
[11]. Here, we confirmed our previous observation in 67 
T-LBL cases by qRT-PCR analysis. Indeed, miR-223 was 
up-regulated up to 400 times compared to normal thymus 
tissue (Figure 1A). Interestingly, the expression levels of 
this miRNA in T-LBL patients displayed a heterogeneous 
distribution (Figure 1B). In order to evaluate the 
prognostic impact of miR-223 expression, we defined two 
groups of patients that express high (above the median 
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value) or low (equal or below the median value) levels of 
miR-223, respectively. The results showed that miR-223 
high level was associated with worse prognosis, with a 
progression-free survival (PFS) of 66% (SE= 8%) for high 
expressing cases vs 94% (SE= 4%) for low expressing (P 
= 0.0036, Figure 1C).
NOTCH1 activation is independent from miR-
223 in T-LBL
Over-expression of miR-223 has been previously 
reported in T-ALL, where it has been shown to regulate 
NOTCH1 signaling by repressing its negative regulator 
FBXW7 [14]. In this context, constitutive activation 
of this signaling pathway is further determined by gain 
of function mutations of NOTCH1 and inactivating 
mutations of FBXW7 [9, 10]. To evaluate the activation of 
NOTCH1 pathway in T-LBL, we first analyzed NOTCH1/
FBXW7 mutational status in all 67 patients. In addition, 
the expression of active intracellular cleaved NOTCH1 
(ICN1) was assessed in 25/67 patients with bioptic material 
available for immunoblotting analysis. NOTCH1 mutations 
were found in 35/67 T-LBL patients (52%), with 28 patients 
having gain-of-function mutations in HD domain and 18 
in PEST domain, respectively (Supplementary Table 2). 
In 11 patients, mutations were detected in both the HD 
and PEST domains. Among HD mutations, 20/28 were 
single amino acid substitutions and 8/28 were in-frame 
insertions or deletions (indels) (Supplementary Figure 1). 
PEST-domain truncating mutations were observed in 11/18 
cases. Of them, 4/11 were non-sense mutations while the 
other 7 were out-of-frame indels. PEST missense mutations 
were detected in 6/18 patients. The remaining patient 
(TLBL74) had a short in-frame insertion (Supplementary 
Figure 1). Point mutations in FBXW7 hot-spot exons were 
detected in 14/67 patients (data not shown). These data 
are consistent with previous reports on pediatric T-LBL 
[4, 7, 8, 13]. The active cleaved form ICN1 was found 
expressed in all 5 NOTCH1 mutated cases and in 14/20 cases 
negative for mutations in HD and PEST domains (Figure 
2A). The activation of NOTCH1 signaling pathway was 
confirmed by measuring the transcript levels of its direct 
target HES1 by qRT-PCR (Figure 2B). As expected, HES1 
transcript levels significantly correlated with ICN1 protein 
expression (Spearman’s correlation coefficient r=0.5777, 
P<0.05). However, the expression level of HES1 was 
not significantly associated to relapse/progression events 
(Fisher’s exact test, P=0.69). Moreover, no significant 
difference was observed between miR-223 levels and ICN1 
expression in tumor biopsies (Fisher’s exact test, P=0.36), 
suggesting that NOTCH1 activation is independent from 
miR-223 expression in lymphoma.
Table 1: Clinical characteristics of the 67 patients with T-LBL
Characteristics Categories # Pts Events 5-y PFS % 
(SE%)
Univariate
P-value
Multivariate
P-value
Hazard Ratio
(95% CI)
Median age ≤ 9.5 yrs
> 9.5 yrs
33
34
6
8
81 (7)
79 (7)
0.76 -
Gender Male
Female
51
16
11
3
78 (6)
88 (8)
0.87 -
Stage I+II
III+IV
7
60
1
13
86 (13)
79 (5)
0.56 -
Mediastinal 
involvement
Yes
No
52
15
9
5
82 (5)
73 (11)
0.31 -
BM involvement Yes
No
10
57
2
12
80 (12)
80 (5)
0.92 -
CNS 
involvement
Yes
No
3
64
2
12
82 (5)
33 (27)
0.052 0.10
NOTCH1 mut No
Yes
32
35
11
3
68 (8)
91 (5)
0.016 0.17
miR-223 
expression level
Low
High
34
33
2
12
94 (4)
66 (8)
0.0036 0.012 6.8 (1.5-30.4)
Low= expression level ≤ median value (18).
High= expression level > median value (18).
BM= bone marrow.
CNS= Central Nervous System.
PFS=Progression-free survival.
Pts=patients.
SE=standard error.
CI=confidence interval.
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Figure 1: Expression levels of miR-223 in T-LBL patients. (A) Boxplot of differential miR-223 expression in T-LBL tumour biopsies 
(n=67) and in normal thymus tissue (n=5) detected by qRT-PCR (**P=0.003). Data have been calculated according to the comparative delta 
Ct method (2-ΔΔCt), using RNU6 as endogenous control. The horizontal line in the box indicates the median expression level of miR-223. (B) 
Heterogeneous expression levels of miR-223 in 67 T-LBL cases. Data have been measured by qRT-PCR according to the comparative delta 
Ct method (2-ΔΔCt), and compared to normal thymus tissue. Blue and red bars are T-LBL tumor biopsies with higher (> median value) and 
lower (≤ median value) level of miR-223, respectively. MiR-223 median expression level=18. (C) PFS according to miR-223 expression 
level. MiR-223 high (>median value), miR-223 low (≤median value).
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Prognostic significance of miR-223 expression 
overcomes NOTCH1/FBXW7 mutational status
To define the prognostic impact of NOTCH1 
mutations in T-LBL, patients were grouped according 
to NOTCH1 and FBXW7 mutational status. As reported 
in other studies [4], NOTCH1mut patients showed 
significantly better outcome than NOTCH1wt, with 91% 
(SE= 5%) vs 68% (SE= 8%) 5-year PFS, respectively 
(P = 0.0156; Figure 3A). The trend was also significant 
when NOTCH1/FBXW7 mutational status was evaluated, 
showing 89% PFS (SE, 5) for mutated vs 67% (SE= 9%) 
for unmutated cases (P = 0.015, Figure 3B), respectively. 
No significant difference was found considering FBXW7 
mutational status alone (P = 0.47, data not shown), in line 
with data previously reported [4]. To further assess the 
role of miR-223 in the outcome of disease, we combined 
miR-223 expression with NOTCH1 mutational status. 
PFS of patients carrying NOTCH1wt and elevated miR-
223 was 63% (SE= 10%) vs 80% (SE= 13%) for patients 
NOTCH1wt with low miR-223 (p=0.006). In contrast, 
patients with NOTCH1mut and elevated miR-223 showed a 
significant inferior PFS compare to those with NOTCH1mut 
with low level of miR-223 (72% SE, 14 vs 100%) (P = 
0.016, Figure 3C). These findings suggested that miR-
223 expression might outweigh the prognostic value of 
NOTCH1 mutations in T-LBL. Indeed, in multivariate 
analysis miR-223 expression level resulted the only 
significant negative prognostic parameter (P=0.012) 
(Table 1).
miR-223 involvement in tumor cell growth, 
migration and invasion
To further elucidate the functional role of miR-223 in 
lymphomagenesis, we evaluated its effect on cell behavior in 
vitro, by transiently over-expressing miR-223 in the T-LBL 
cell line SUPT-1 and inducing its inhibition in the T-ALL 
cell line Jurkat. We choose these cell lines for their low and 
high endogenous expression level of miR-223, respectively 
[14] (Supplementary Figure 2). MiR-223 expression level 
was evaluated by qRT-PCR at different time points after 
transfection (Supplementary Figure 3). MTT assay showed an 
increase of cell growth to 25% in SUPT-1 cells at 72 h, while 
a 20% reduction in Jurkat cells (data not shown). In addition, 
we observed an increase of clonogenic growth capacity in 
SUPT-1 over-expressing miR-223 (Figure 4A). Interestingly, 
miR-223 over-expressed in SUP-T1 incremented significantly 
Figure 2: NOTCH1 pathway activation in T-LBL primary tumors. (A) Western blotting analysis of intracellular cleaved 
NOTCH1 in T-LBL tumour biopsies. Blue line: patients with miR-223 high expression level; red line: patients with miR-223 low expression 
level. Lysates from cell lines MOLT-4 and Jurkat were included as positive controls. γ-tubulin was used as loading control. Vertical lines 
have been inserted to indicate repositioned gel lanes. (B) Expression levels of HES1 mRNA in primary tumors measured by qRT-PCR. 
Data have been calculated according to the comparative delta Ct method (2-ΔΔCt), using ABL gene as endogenous control. Relapsed patients 
are indicated with *.
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Figure 3: Prognostic significance of NOTCH1 and FBXW7 mutational status and miR-223 expression level. Outcome 
of 67 pediatric patients with T-LBL stratified by NOTCH1 and FBXW7 mutational status. PFS according to mutation of NOTCH1 (A), 
NOTCH1 and/or FBXW7 (B). (C) PFS according to mutation of NOTCH1 and miR-223 expression level. MUT, mutated; WT, wild type. 
MiR-223 high (>median value), miR-223 low (≤median value).
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migration and invasion compared to control cells (Figure 4B). 
Consistently, the inhibition of miR-223 in Jurkat cells led to a 
reduction in clonogenicity and motility after transfection with 
miR-223 inhibitor compared to control (Figure 4C and 4D). 
Taken together, these results suggest that miR-223 is involved 
in tumorigenic processes of lymphoma and contribute in 
promoting cell aggressiveness.
miR-223 down-regulates the expression of SIK1 
and contributes to a more aggressive phenotype 
in pediatric T-LBL patients
Based on a previous analysis that we performed 
to identify context-specific miRNA targets in T-LBL by 
integrating computational predictions of miRNA targets with 
T-LBL microRNA and gene expression data [11], SIK1 (Salt-
inducible kinase 1) emerged as a strong candidate to be a 
direct target of miR-223 in T-LBL (P <0.0001). SIK1 is an 
important regulator of anoikis and its loss has been shown 
to facilitate metastatic spread and survival of disseminated 
cells as micrometastases in solid tissues such as lungs [16]. 
Thus, by using the bioinformatics tool MicroRNA.org, we 
found that SIK1 3’-UTR is characterized by two putative 
binding sites for miR-223 in the up- and down-stream 
regions that we named UTR-1 and UTR-4, respectively 
(Supplementary Figure 4). Direct modulation by miR-223 of 
SIK1 was confirmed by 3’UTR luciferase assay in SUPT-
1 T-LBL cell line transfected with miR-223 or negative 
control and reporter vectors containing the entire 3’-UTR of 
SIK1 divided in 4 portions, namely UTR-1, 2, 3 and 4. We 
observed a significant reduction (20%) in luciferase activity 
in construct containing the UTR-4 portion of SIK1 3’-UTR, 
an effect that was abrogated by point mutations in the miR-
223 interacting region of the 3’-UTR of SIK1 (Figure 5A). No 
Figure 4: miR-223 involvement in tumor cell growth, migration and invasion. SUPT-1 cells that express low levels of miR-
223 were transiently transfected with miR-223 precursor (mimic) or its negative control (NC) and used to analyze clonogenicity (A) or 
migration and invasion (B). Conversely, Jurkat cells, that expresses high level of miR-223, were transiently transfected with inhibitor (anti-
miR or anti-control) and used to analyze clonogenicity (C) or migration and invasion (D). The results are shown as number of colonies 
measured at 10 days by colony assay (A-C), and percentage (%) of migration and invasion by Transwell-migrating or Matrigel-invading 
cells (B-D). Clonogenicity, migration and invasion of miR-modulated cells are shown relative to negative control values. Two or three 
independent experiments were performed in triplicate and mean results are shown. *P<0.05; **P<0.001.
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Figure 5: miR-223 modulates the expression of SIK1. SUPT-1 cells transfected with miR-223 precursor analyzed 24 h post-
transfection were used to perform Luciferase assay in cells transfected with reporter containing wild-type or mutant (mutated) binding sites 
in SIK1 3’-UTRs. Results from three independent experiments are shown as mean ± SEM of Firefly luciferase activity relative to controls 
(NC), normalized on Renilla luciferase activity. *P<0.05, (A). Boxplot represents the analysis of SIK1 protein expression in T-LBL tumour 
biopsies detected by immunoblotting. Density expression level was normalized on tubulin. The horizontal line in the box indicates the 
median expression level of SIK1 in the two miR-223 subgroups (miR-223-low and -high) of T-LBL cases. *P<0.05 (B). SIK1 staining in 
T-LBL specimens, belong to miR-223-low (T-LBL_29,63,50) and -high groups (T-LBL_73,66,31) (× 40) (C).
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significant effect was observed in UTR-1 (data not shown). 
Moreover, no repression was seen in cells transfected with 
portions UTR-2 and UTR-3, confirming that these sequences 
are not directly targeted by miR-223 (data not shown). In 
support of the modulation of SIK1 by miR-223, we found 
a marked decrease of SIK1 protein expression in miR-223 
over-expressing SUP-T1 cell line up to 72h post-transfection, 
when analyzed by immunoblotting analysis (Supplementary 
Figure 3). This evidence was not observed in Jurkat cells 
after inhibition of miR-223. Thus, we examined SIK1 protein 
expression in available tumour biopsies by immunoblotting 
(Supplementary Figure 5). Interestingly, the results showed 
that SIK1 protein level was significantly decreased in 
patients expressing high levels of miR-223 (Figure 5B). 
Notably, in all relapsed patients miR-223 was high and 
SIK1 protein was almost undetectable. Furthermore, when 
tumour biopsies were assessed for protein expression by 
immunohistochemistry, SIK1 was found weakly expressed in 
high miR-223 cases (Figure 5C), suggesting that high levels 
of miR-223 could function as oncomir by SIK1 repression.
DISCUSSION
Identification of biological markers that can 
predict outcome in T-LBL is crucial to allow for 
treatment optimization and may serve as targets 
for new treatment strategies. Several recent studies 
have revealed that microRNAs are involved in the 
development of tumors [17]. The biologic role of 
microRNAs may vary according to their expression in 
distinct cell populations of normal or neoplastic tissues. 
Here, we report that expression levels of miR-223 
constitute a strong prognostic factor in pediatric T-LBL 
patients homogeneously treated according to BFM-type 
strategy. Indeed, we showed that high levels of miR-
223 expression are associated with worse prognosis. 
This study demonstrates, for the first time, that a single 
noncoding RNA associates with clinical outcome in 
T-LBL, in the context of the well-established molecular 
marker NOTCH1. Of note, when we combined miR-223 
expression levels and NOTCH1 mutational status, we 
observed that miR-223 outweighs the prognostic value 
of NOTCH1. Existing evidence in T-ALL showed miR-
223 as promoter in the development of leukemia [12] and 
it was demonstrated that over-expression of miR-223 is 
an additional way of NOTCH1 signaling activation [18]. 
Our data suggest that in T-LBL, unlike T-ALL, miR-223 
expression and NOTCH1 pathway activation are not 
correlated. Indeed, both T-LBL and T-ALL represent 
T-cell progenitor malignancies, that share overlapping 
clinical, morphological and immunophenotypic features, 
however comparative genomic studies revealed that, 
despite having some genetic similarities, these two 
manifestations of T-cell malignancy may reflect distinct 
biological entity [19, 20]. Our results corroborate these 
data, highlighting that miR-223 over-expression affects 
the aggressiveness of the disease. Based on miRNA-
target predictions, we found SIK1 protein as a putative 
target of miR-223. SIK1 kinase has been identified as 
a key modulator of anoikis (apoptosis induced by cell 
detachment) and its inactivation compromised the 
tumor suppressor p53 function, allowing metastatic 
growth in transplanted tumor cells [21]. Reduced SIK1 
expression is correlated with poor prognosis in two 
large human breast cancer data sets [16]. No data are 
available regarding SIK1 expression in pediatric tumors 
and in particular in T-LBL. Here we demonstrated that 
SIK1 is one of the targets of miR-223. Consistent with 
the findings of previous studies reporting that SIK1 
prevents metastasis and tumor invasion [16], we found 
that SIK1 can be down-regulated in T-LBL tumour 
tissues, suggesting its association with the T-LBL disease 
progression and its potential use as predictor marker for 
patient risk stratification at diagnosis. Indeed, we found 
a significant different expression level of SIK1 protein 
in T-LBL cases based on miR-223 expression level. 
Noteworthy, all relapsed patients displayed high level of 
miR-223 and very low level of SIK1 at diagnosis. Based 
on our multivariate analysis, the negative prognostic 
power of miR-223 could be considered to identify high 
risk patients that could be treated with an intensification 
of current therapies. MiR-223 expression level analysis 
in tumour tissue of a larger cohort of patients will 
contribute to confirm the importance of this molecular 
marker for risk-based treatment stratification in T-LBL.
MATERIALS AND METHODS
Patients and methods
Between June 2000 and May 2012, 114 consecutive 
children with T-LBL were enrolled in an NHL-BFM-type 
treatment protocols (AIEOP LNH-97 or EuroLB-02) [7, 
22]. Of these, 67 patients had available tumor specimens 
for both NOTCH1/FBXW7 mutational analysis and miR-
223 expression level evaluation. The availability of tumor 
specimens was the only selection criteria. The infantile 
normal thymuses had been removed during cardiothoracic 
surgical procedures and were obtained from our hospital. 
Protocols were approved by the ethics committee or by 
the internal review board of each participating institution, 
and inform consent was obtained from parents or legal 
guardians before patient enrollment. The diagnosis of 
T-LBL was established from clinical, histological, and 
immunohistochemistry findings. Tumor biopsies were 
classified according to WHO guidelines [23]. In all 
cases, the histological diagnosis was centrally reviewed. 
Samples were collected in accordance with the tenets of 
the Declaration of Helsinki. Ethics approval and consent 
to participate this study was approved by the Ethics 
Committee, Padua Hospital. Written informed consent was 
obtained from all subjects.
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NOTCH1 and FBXW7 mutational analysis
Genomic DNA was obtained from tumor tissue 
biopsies or pleural/pericardial effusion of T-LBL cases, 
as described previously [24]. Exons 26 and 27, encoding 
for NOTCH1 heterodimerization domain (HD), exon 34, 
encoding the transactivation domain (TAD) and PEST 
domains, and FBXW7 exons 9, 10 and 12 were amplified 
as previously reported [4]. PCR products were sequenced 
on a 3500 DX Genetic Analyzer (Life Technologies, CA, 
USA), either directly or after subcloning into Topo TA 
cloning vector (Life Technologies). GeneBank accession 
numbers NM_017617.3 and NM_033632.3 were used as 
reference sequences.
qRT-PCR for miRNA or mRNA detection
Total RNA was isolated using Trizol Reagent (Life 
Technologies), as described previously [25]. Validation of 
miRNA detection for in vitro experiments was performed 
using TaqMan® MicroRNA Reverse Transcription kit and 
TaqMan® Universal PCR Master Mix No Amperase® 
UNG (Life Technologies). Three replicates of each 
sample and endogenous control were amplified for each 
real-time PCR (qRT-PCR) reaction. For mRNA detection, 
1 μg of total RNA was retrotranscribed with SuperScript 
II reverse transcriptase (Life Technologies) and random 
hexamers, and qRT-PCR was carried out using TaqMan® 
Universal PCR Master Mix (Life Technologies). Each 
sample was analyzed in triplicate. The expression 
levels of specific targets of interest were assessed using 
hsa-miR-223 (ID 002295), HES1 (ID 00172878_m1) 
(Life Technologies). RNU6B small nuclear RNA (ID 
001093) (Life Technologies) or ABL [11] were chosen, 
as endogenous normalizers of the expression of miRNA 
or mRNAs, respectively. The relative expression levels 
between samples were calculated using the comparative 
delta Ct (threshold cycle number) method (2-ΔΔCt).
Immunoblotting analysis
Sample lysates were prepared by SDS-buffer 
(1% SDS; 1 mM PMSF; 20 μg/mL leupeptin; 20 μg/
mL aprotinin; 1:100 phosphatase inhibitor cocktails 2 
and 3) to dissolve the pellet before SDS-PAGE analysis. 
Protein concentration was determined by BCA protein 
assay (Thermo Scientific Pierce, Milano, Italy), and equal 
amounts of proteins (50 μg) were resolved by SDS-PAGE 
prior to be transferred onto nitrocellulose membranes 
(PerkinElmer, MA, USA). Blocked membranes were 
probed for Notch1Val1744 (rabbit, 1:1000, Cell Signaling, 
MA, USA) and SIK1 (Y-20) (rabbit, 1:2000, Santa Cruz, 
CA, USA), using γ-tubulin (mouse, 1:4000, SIGMA, 
Milan, Italy) as gel loading control. Membranes were 
incubated with peroxidase-labeled donkey anti-rabbit 
IgG (1:2000, GE Healthcare, UK) or peroxidase-labeled 
sheep anti-mouse IgG (1:2000, GE Healthcare, UK) 
and visualized with ECL Pro chemiluminescent solution 
(PerkinElmer, MA, USA) and Hyperfilm autoradiography 
films (GE Healthcare, UK).
Cell culture
Human cell lines SUPT-1 (NIBSC, UK) and Jurkat 
(ATCC, USA), were maintained in RPMI 1640 medium 
contained 10% heat-inactivated fetal calf serum (FCS), 2 
mmol/L glutamine, 100 U/mL penicillin, and 100 μg/mL 
streptomycin at 37°C in 5% CO2 in a humidified incubator. 
All reagents were purchased from Life Technologies.
Transient transfection of pre-miRNA or anti-
miRNA
Pre-miRNA negative control (EX479903001), 
anti-miRNA negative control (EX199006101, power 
inhibitor control), miRNA precursor (EX47XXXX001) 
and inhibitor (EX410XXX101) hsa-miR-223-3p were 
purchased from Exiqon (Exiqon miRCURY LNA, 
Denmark). To induce transient pre-miR or anti-miR 
expression, SUPT-1 and Jurkat cells were transfected 
with 50 nM pre-miR-223/control or with 100 nM anti-
miR-223/control respectively, using Amaxa® Cell Line 
Nucleofector® Kit V (Lonza, Visp, CH) following the 
manufacturer’s instructions. Cells were harvested 24 h 
after transfection and miR-223 expression was assessed 
by qRT-PCR.
MTT assay
SUP-T1 and Jurkat cell growth was assessed by 
MTT (3-4,5-dimethylthiazol-2,5-diphenyltetrazolium; 
SIGMA, Milan, Italy). The cells were grown after 
transfection up to 72 h and MTT salt reduction was 
measured each day at a 540 nm optical density (O.D.). 
Values were calculated as mean ±SD of triplicate cultures 
of three independent experiments.
Migration, invasion and clonogenic assays
Migration was tested using cell culture inserts 
(Transwell) with a 5-μm pore size membrane (24-well 
format; Corning, MA, USA). Invasion was measured 
using 5-μm pore polycarbonate filter coated with Matrigel 
(Becton Dickinson, NJ, USA). The lower compartment 
contained 0.5 ml of 10% serum medium conditioned 
by 80 ng CXCL12 (Peprotech, London, UK) as a 
chemoattractant or serum-free RPMI medium as a control. 
In the upper compartment, 3x105 SUPT-1 or Jurkat cells 
per well were placed in triplicate and incubated up to 
desired time point at 37°C in a humidified incubator with 
a 5% CO2 atmosphere. After incubation, the cells on the 
lower surface were counted. For clonogenic assay, SUPT-1 
or Jurkat cells were incubated in the medium MethoCult™ 
H4230 (STEMCELL™, Hong Kong) at a cell density of 
Oncotarget11www.impactjournals.com/oncotarget
2×104 cells/ml for 10 days. For all the assays, cells were 
previously transfected with mimic or inhibitor of miR-223 
and relative negative controls. Numbers of colonies were 
counted according to the manufacturer’s instructions.
Luciferase reporter assay
The 3’-UTR region of the predicted miR-223 target 
gene SIK1 was amplified from human genomic DNA and 
cloned into the pmirGLO Dual-Luciferase miRNA Target 
Expression Vector (Promega, Milan, Italy). To confirm 
the binding of miR-223 to the 3’-UTR sequence of SIK1, 
SUPT-1 cells (1x106) were co-transfected with 50 ng of 
the pmirGLO dual-luciferase constructs containing the 
3’-UTR of SIK1 and 50 nM of pre-miR-223 or miRNA 
negative control. Lysates were collected 24 h after 
transfection and Firefly and Renilla Luciferase activities 
were measured with a Dual-Luciferase Reporter System 
(Promega, Milan, Italy). Relative luciferase activity 
was calculated by normalizing the ratio of Firefly/
Renilla luciferase to negative control-transfected cells. 
Transfections were performed in triplicate. Moreover, 
the 3’-UTR construct was mutagenized at the miR-223 
binding site using the Phusion Site-Directed mutagenesis 
kit (Thermo Fisher Scientific, MA, USA) following the 
manufacturer’s instructions.
Immunohystochemistry
SIK1 protein expression was tested by 
immunohistochemistry on 6 formalin-fixed paraffin-
embedded T-LBL tumor specimens using the SIK1 
(Y-20) antibody (1:200 dilution, Santa Cruz), after 
deparaffinisation and antigen retrieval. Detection was 
performed using a biotinylated secondary antibody and 
a DAB chromogen in haematoxylin counterstained 
cells (Vectastain ABC Kit Elite, PK-6100, Vector Labs, 
Burlingame, CA, USA). Each case was considered 
positive when more than 50% of the cells had moderate-
to-strong cytoplasmic staining.
Statistical analyses
Data analysis were carried out by using the SAS 
statistical program (SAS-PC, version 9.3; SAS Institute Inc., 
Cary, NC, USA) and GraphPad Prism 7.0. Probability of 
progression-free survival (PFS) was analyzed by the Kaplan–
Meier method and difference among patient subsets compared 
by log-rank test [26]. PFS was calculated from the date of 
diagnosis to the date of progression or relapse or to the date 
of the last follow-up. Univariate comparisons were performed 
according to the log-rank test, whereas the Cox model [27] 
was performed to examine the risk factors affecting the PFS 
in the multivariate analyses, including variable with P<0.2 in 
univariate analysis. Descriptive statistics were used to define 
population. The Spearman’s correlation coefficient was 
used to measure the association between active intracellular 
cleaved NOTCH1 expression and HES1 transcript levels. The 
Fisher’s exact test was used to evaluate the association among 
NOTCH1 activation and miR-223 expression. The t-test was 
used to determine differences in cell growth, migratory and 
invasion potential and luciferase activity between different 
experimental conditions. A P-value less than 0.05 was 
considered statistically significant. All P-values are two-sided, 
with a type I error rate fixed at 0.05.
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